adm glp-1 ADM: 83% of users are 'very interested in products specifically marketed as supportive of their needs on these drugs' ADM Launches GLP-1 Supportive Solutions
Description
doi:10.1002/oby.24172
The Heavy Price of GLP-1 Drugs reveals how pharmaceutical companies are exploiting the patent system, delaying competition, and driving up costs for patients
Brookfield, WI
Easy once-a-day use
